Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (1008)	6/9/2005 12:05:53 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

Ray: Re: AMLN It is bouncing up from its 52wks. L yesterday at the 14.50 level, after the news that BYETTA is now available in pharmacies across the country.<g> The stock is up about 5.87% and volume is over 1.8M (not impressive, since the day of the down-gap on Apr.29 the volume was over 20M) That downgap was closed, but the stock needs to close above its June 6 H of 16.60 before it could test the higher resistance at the 17.90 to 18.06 level (from the mid May Hs and the May 2 "rebound" after the Apr.29 down-gap) bigcharts.marketwatch.com As you know, BYETTA is available as an adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who have not achieved adequate control on metformin or sulfonylureas. It is the first of the "incretin mimetics", a new class of treatment for DM, which is supposed to work by copying the action of the hormone.It supposedly is "self regulating" and works only when blood sugar gets too high, so it supposedly shouldn't cause hypoglycemia.(Although apparently there have been some reports and the main "side effect" is nausea).In the results of the trial done in conjunction with LLY the patients on BYETTA also had some weight loss.<g> More than half of type2 diabetics aren't having good control of their BS and BYETTA is supposed to help better control. Is like providing insulin after food intake or a rise in BS.So the drug seems to have a good potential for large demand. But of course type2 diabetics are not used to have daily or 2x daily injections.<g> RAGL Bernard